Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTENUATION adjuvant chemotherapy de-escalation study in low-risk localized gastroesophageal adenocarcinoma
2023-509227-41-00Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Jul 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, oxaliplatin, folinic acid and fluorouracil in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Centre Léon Bérard. Primary endpoint: 3-year overall survival rate. Started Jul 2024; status: completed.
02
Drugs
docetaxeloxaliplatinfolinic acidfluorouracil
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2023-509227-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509227-41-00.